|Articles|May 1, 2020
- Pharmaceutical Executive-05-01-2020
- Volume 40
- Issue 5
Pharmaceutical Executive, May 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive May 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Pharm Exec's Emerging Pharma Leaders 2020almost 6 years ago
AI: Kickstarting the Race Against COVID-19almost 6 years ago
Competition for Biotech CFOs is Heating Upalmost 6 years ago
Biopharma Sustainability Considered Essentialalmost 6 years ago
CFOs Outlook: Forging a Sustainable Futurealmost 6 years ago
Drive for COVID-19 Therapies Raises Patent and Pricing Issuesalmost 6 years ago
Biotech in the Age of COVID: The Pain and the Gainalmost 6 years ago
A New, Less Friendly Normal Looms for European Drugmakersalmost 6 years ago
How Prepared Were Doctors for the COVID Digital Upswing?almost 6 years ago
Pharmaceutical Executive, May 2020 Issue (PDF)Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5
